Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 9, 1996, Pages 2194-2199

  Nicas, Thalia I ^a   Mullen, Deborah L ^a   Flokowitsch, Jane E ^a   Preston, David A ^a   Snyder, Nancy J ^a   Zweifel, Mark J ^a   Wilkie, Stephen C ^a   Rodriguez, Michael J ^a   Thompson, Richard C ^a   Cooper, Robin D G ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROORIENTICIN A; GLYCOPEPTIDE; POLYPEPTIDE ANTIBIOTIC AGENT; TEICOPLANIN; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; COAGULASE NEGATIVE STAPHYLOCOCCUS; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; GRAM POSITIVE BACTERIUM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; STAPHYLOCOCCUS EPIDERMIDIS; STRAIN DIFFERENCE; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

EID: 9544220776     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.9.2194     Document Type: Article

References (30)

1. Al-Obeid, S., L. Gutmann, D. M. Shlaes, R. Williamson, and E. Collatz. 1990. Comparison of vancomycin-inducible proteins from four strains of enterococci. FEMS Microbiol. Lett. 70:101-106.
2. Arthur, M., C. Molinas, F. Depardieu, and P. Courvalin. 1993. Characterization of Tn1546, a Tn3-related transposon conferring glycopeptide resistance by synthesis of depsipeptide peptidoglycan precursors in Enterococcus faecium BM4147. J. Bacteriol. 175:117-121.
3. Beauregard, D. A., D. H. Williams, M. N. Gwynn, and D. J. C. Knowles. 1995. Dimerization and membrane anchors in the extracellular targeting of vancomycin group antibiotics. Antimicrob. Agents Chemother. 39:781-785.
4. Breen, J. D., C. Thauvin-Eliopoulos, G. M. Eliopoulos, and R. C. Moellering, Jr. 1995. Activity of new semisynthetic glycopeptides against vancomycin-resistant (vr) organisms, abstr. F253, p. 157. In Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
5. Bugg, T. H., S. Dutka-Malen, M. Arthur, P. Courvalin, and C. T. Walsh. 1991. Identification of vancomycin resistance protein VanA as a D-alanine: D-alanine ligase of altered substrate specificity. Biochemistry 30:2017-2021.
6. Centers for Disease Control. 1993. Nosocomial enterococci resistant to vancomycin - United States. Morbid. Mortal. Weekly Rep. 45:597-599.
7. Cooper, R. D. G., B. E. Huff, T. I. Nicas, J. Quatroche, M. Rodriguez, N. Snyder, M. Styaszak, R. Thompson, S. Wilkie, and M. Zweifel. U.S. patent application EP0667353A: glycopeptide antibiotic derivatives.
8. Cooper, R. D. G., N. J. Snyder, M. J. Zweifel, M. A. Staszak, S. C. Wilkie, T. I. Nicas, D. L. Mullen, T. F. Butler, M. J. Rodriguez, B. E. Huff, and R. C. Thompson. 1996. Reductive alkylation of glycopeptide antibiotics: synthesis and antibacterial activity. J. Antibiot. 49:575-581.
9. Goldstein, B. P., G. Candiani, T. M. Arain, G. Romanò, I. Ciciliato, M. Berti, M. Abbondi, R. Scotti, M. Mainini, F. Ripamonti, A. Resconi, and M. Denaro. 1995. Antimicrobial activity of MDL 63,246, a new semisynthetic glycopeptide antibiotic. Antimicrob. Agents Chemother. 39:1580-1588.
10. Handwerger, S., B. Raucher, D. Altarac, J. Monka, S. Marchione, K. Y. Singh, B. E. Murray, J. Wolff, and B. Walters. 1993. Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin, and gentamicin. Clin. Infect. Dis. 16:750-755.
11. Hobbs, J. N., Jr., D. L. LeTourneau, T. I. Nicas, and N. E. Allen. 1995. Effects of N-alkyl derivatives of LY264826 on peptidoglycan biosynthesis in vancomycin-resistant Enterococcus faecium, abstr. F251, p. 157. In Program and abstracts of the 35th Intersciencc Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
12. Jett, B., L. Free, and D. F. Sahm. 1996. Factors influencing the Vitek Gram-Positive Susceptibility system's detection of vanβ-encoded vancomycin resistance among enterococci. J. Clin. Microbiol. 34:701-706.
13. Johnson, A. P., A. H. C. Uttley, N. Woodford, and R. C. George. 1990. Resistance to vancomycin and teicoplanin: an emerging clinical problem. Clin. Microbiol. Rev. 3:280-291.
14. Jones, R. N., H. Sader, M. E. Erwin, S. C. Anderson, and The Enterococcus Study Group. 1995. Emerging multiply resistant enterococci among clinical isolates. Diagn. Microbiol. Infect. Dis. 21:85-93.
15. Kenny, M. T., M. A. Brackman, and J. K. Dulworth. 1995. In vitro activity of the semisynthetic glycopeptide amide MDL 63,236. Antimicrob. Agents Chemother. 39:1589-1590.
16. LeTourneau, D. L., J. N. Hobbs, Jr., and N. E. Allen. 1995. Molecular interactions of LY264826 and its p-chlorobenzyl derivative, LY191145, with dipeptidyl and didepsipeptidyl ligands, abstr. F250, p. 157. In Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
17. Malabarba, A., R. Ciabatti, R. Scotti, B. P. Goldstein, P. Ferrari, M. Kurz, B. Andreini, and M. Denaro. 1995. New semisynthetic glycopeptides MDL 63,246 and MDL 63,042, and other amide derivatives on antibiotic A-40,926 active against highly glycopeptide-resistant VanA enterococci. J. Antibiot. 48:869-883.
18. Nagarajan, R. 1993. Structure-activity relationships of vancomycin-type glycopeptide antibiotics. J. Antibiot. 46:1181-1195.
19. National Committee for Clinical Laboratory Standards. 1990. Approved standard M7-A2. Methods for dilution antimicrobial susceptibility testing for bacteria that grow aerobically, 2 ed. National Committee for Clinical Laboratory Standards, Villanova, Pa.
20. Nicas, T. I., D. L. Mullen, J. E. Flokowitsch, D. A. Preston, N. J. Snyder, R. E. Stratford, and R. D. G. Cooper. 1995. Activities of the semisynthetic glycopeptide LY191145 against vancomycin-resistant enterococci and other gram-positive bacteria. Antimicrob. Agents Chemother. 39:2585-2587.
21. Nicas, T. I., D. L. Mullen, and J. Grissom-Arnold. 1996. Ability of semisynthetic glycopeptide antibiotics active against vancomycin-resistant enterococci to act on expression of vancomycin resistance, abstr. A74, p. 112. In Abstracts of the 96th General Meeting of the American Society for Microbiology 1996. American Society for Microbiology. Washington, D.C.
22. Noble, W. C., Z. Virani, and R. G. Cree. 1992. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol. Lett. 72:195-198.
23. Reed, L. J., and J. Muench. 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27:493-497.
24. Reynolds, P. E. 1989. Structure, biochemistry, and mechanism of action of glycopeptide antibiotics. Eur. J. Clin. Microbiol. Infect. Dis. 8:789-803.
25. Schwalbe, R. S., J. T. Stapleton, and P. H. Gilligan. 1987. Emergence of vancomycin resistance in coagulase-negative staphylococci. N. Engl. J. Med. 316:927-931.
26. Shlaes, D. M., A. Bouvet, C. Devine, J. H. Shlaes, S. Al-Obeid, and R. Williamson. 1989. Inducible, transferable resistance to vancomycin in Enterococcus faecalis A256. Antimicrob. Agents Chemother. 33:198-203.
27. Uttley, A. H. C., C. H. Collins, J. Naidoo, and R. C. George. 1988. Vancomycin-resistant enterococci. Lancet i:57-58.
28. Walsh, C. T. 1993. Vancomycin resistance: decoding the molecular logic. Science 261:308-309.
29. Williams, D. H., and J. P. Waltho. 1988. Molecular basis of the activity of antibiotics of the vancomycin group. Biochem. Pharmacol. 17:133-141.
30. Woodford, N., A. P. Johnson, D. Morrison, and D. C. E. Speller. 1995. Current perspectives on glycopeptide resistance. Clin. Microbiol. Rev. 8:585-615.